Cargando…

SDPS-10 DISPARITIES IN THE RISK OF CNS METASTASIS AND CLINICAL OUTCOMES IN PATIENTS WITH HER2- MUTATION POSITIVE (HER2+) NON-BREAST VERSUS HER2+ BREAST CANCERS

BACKGROUND: Risk of CNS metastases is well characterized for patients (pts) with HER2+ breast cancer (BC), however, poorly defined for pts with HER2+ non-breast solid tumors (ST). METHODS: We performed a retrospective cohort analysis to characterize the frequency of CNS metastasis and clinical outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elghawy, Omar, Horton, Bethany, Shen, Shiyi, Kaur, Varinder
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Screening/Diagnostics/Prognostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402440/ http://dx.doi.org/10.1093/noajnl/vdad070.070

Ejemplares similares

SDPS-46 CENTRAL NERVOUS SYSTEM (CNS)-RELATED MORTALITY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
por: Ferraro, Emanuela, et al.
Publicado: (2023)

SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
por: Kumthekar, Priya, et al.
Publicado: (2023)

SDPS-25 COMPARISON OF MOLECULAR ALTERATIONS BETWEEN SYSTEMIC AND CNS METASTATIC SITES REVEALSMUTATIONAL DISCORDANCES
por: Huang, David, et al.
Publicado: (2023)

SDPS-41 PATHOMICS AUGMENTS PREDICTIVE SURVIVAL MODELLINGIN MEDULLOBLASTOMA
por: Mahtabfar, Aria, et al.
Publicado: (2023)

SDPS-31 EXTRACELLULAR VESICLES AND THEIR CARGO AS A PHARMACODYNAMIC REPORTER IN GLIOBLASTOMA
por: DeLuca, Valerie, et al.
Publicado: (2023)

SDPS-38 A BRAIN METASTASES PREDICTION MODEL IN BREASTCANCER WOMEN
por: Cacho-Díaz, Bernardo, et al.
Publicado: (2023)

SDPS-45 PROGNOSTIC CHARACTERIZATION OF GENETIC MARKERS IN GLIOMA-ASSOCIATED EPILEPSY
por: Guo, Lydia, et al.
Publicado: (2023)

SDPS-27 P16 IMMUNOHISTOCHEMISTRY AS A SCREENING TOOL FOR HOMOZYGOUS CDKN2A DELETIONS IN GLIAL TUMORS
por: Zschernack, Valentina, et al.
Publicado: (2023)

SDPS-43 OUTCOMES OF SUPRATENTORIAL FOCAL ENHANCING LESIONS CONCERNING FOR LEPTOMENINGEAL METASTASES
por: Rodriguez, Andrew, et al.
Publicado: (2023)

SDPS-40 MEDULLOBLASTOMA MOLECULAR SUBTYPE PREDICTION USING PATHOMIC FEATURE ANALYSIS
por: Mahtabfar, Aria, et al.
Publicado: (2023)

SDPS-44 RAPID DETECTION OF MUTATIONS IN CSF-CFTNA WITH THE GENEXUS INTEGRATED SEQUENCER
por: Arjuna, Srividya, et al.
Publicado: (2023)

SDPS-28 THE STUDY OF AN ANOIKIS-RELATED SIGNATURE TO PREDICT GLIOMA PROGNOSIS AND IMMUNE INFILTRATION
por: Zhang, Dongdong, et al.
Publicado: (2023)

SDPS-36 CLINICAL PRESENTATION IS A USEFUL PROGNOSTIC MARKER IN PATIENTS WITH BRAIN METASTASES
por: Cacho-Díaz, Bernardo, et al.
Publicado: (2023)

SDPS-13 CELL LINE STUDY OF NUCLEOSOME-BASED BIOMARKERS IN THE DIAGNOSIS AND DETECTION OF RELAPSES IN GLIOBLASTOMA
por: Decarpentrie, Jonathan, et al.
Publicado: (2023)

SDPS-08 OSSEOUS METASTASES IN H3G34-MUTANT DIFFUSE HEMISPHERIC GLIOMAS
por: Yu, Nina, et al.
Publicado: (2023)

SDPS-14 CLINICAL FEATURES AND OUTCOME IN CHILDREN WITH CHOROID PLEXUS CARCINOMA-A SINGLE CENTER EXPERIENCE
por: Li, Miao, et al.
Publicado: (2023)

SDPS-35 TUMOR-RELATED EPILEPSY IN HIGH-GRADE GLIOMA: A LARGE SERIES SURVIVAL ANALYSIS
por: Rilinger, Ryan, et al.
Publicado: (2023)

SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
por: Li, Juan, et al.
Publicado: (2023)

SDPS-23 CUMULATIVE TUMOR VOLUME THRESHOLD CORRELATES WITH NEUROCOGNITIVE IMPAIRMENT IN PATIENTS WITH NEWLY DIAGNOSED BRAIN METASTASES
por: Zhen, Junjie, et al.
Publicado: (2023)

SDPS-16 CYTOLOGIC AND SEROLOGIC RESPONSE WITH INTRATHECAL METHOTREXATE IN A PATIENT WITH LEPTOMENINGEAL CARCINOMATOSIS FROM OVARIAN CANCER
por: Cordova, Christine, et al.
Publicado: (2023)

SDPS-17 COMPREHENSIVE ANALYSIS OF CELL DIVISION CYCLE ASSOCIATED GENE FAMILY EXPRESSION PATTERN AND PROGNOSIS VALUE REVEALS CDCA2 AS A NOVEL ONCOGENE FOR GLIOMA
por: Sun, Wei, et al.
Publicado: (2023)

SDPS-11 IMPACT OF MOLECULAR MARKERS USING FISH TECHNIQUE ON GOS/SURVIVAL IN HIGH GRADE GLIOMAS IN INDIAN SCENARIO
por: Pathak, Ashis, et al.
Publicado: (2023)

SDPS-42 METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN EDEMA: A TOPOGRAPHICAL AND CLINICOPATHOLOGIC INVESTIGATION
por: Yun, Jonathan, et al.
Publicado: (2023)

SDPS-47 CIRCULATING TUMOR CELL ANALYSIS FROM THE CEREBROSPINAL FLUID INFORMS EARLY DIAGNOSIS, TREATMENT AND PROGNOSIS IN LEPTOMENINGEAL CARCINOMATOSIS
por: Sandri, Andrea, et al.
Publicado: (2023)

SDPS-30 ANALYSIS OF THE BRAIN TUMOR MATRISOME REVEALS CANCER ASSOCIATED FIBROBLASTS PREDICT POOR IMMUNOTHERAPY RESPONSE IN GLIOBLASTOMA PATIENTS
por: Zarodniuk, Maksym, et al.
Publicado: (2023)

SDPS-34 SCREENING TUMOR INFILTRATING LEUKOCYTES IN GLIOBLASTOMA REVEALS A CORRELATION WITH EGFR POSITIVE TUMOR CELLS WITH PROGNOSTIC IMPLICATIONS
por: Goodyke, Austin, et al.
Publicado: (2023)

SDPS-26 UNINTENDED RADIOTHERAPY DOSE ON THE NEUROGENIC NICHES IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL IN PATIENTS WITH LUNG CANCER BRAIN METASTASES
por: Cialdella, Fia, et al.
Publicado: (2023)

SDPS-32 A CLINICALLY COMPATIBLE IN VITRO DRUG-SCREENING PLATFORM IDENTIFIES THERAPEUTIC VULNERABILITIES IN PRIMARY CULTURES OF BRAIN METASTASES
por: Jeising, Sebastian, et al.
Publicado: (2023)

SDPS-37 IDENTIFICATION OF TIME-COURSE RELATED, TREATMENT-RELATED, AND PATIENT-RELATED PROGNOSTIC FACTORS IN BRAF-MUTANT MELANOMA BRAIN METASTASES.
por: Erickson, Lily G, et al.
Publicado: (2023)

SDPS-39 AN UPDATED VALIDATION OF PREDICTIVE ALGORITHMS FOR BRAIN METASTASES IN NON-SMALL CELL LUNG CANCER: SYSTEMATIC REVIEW AND INDEPENDENT COHORTVALIDATION ANALYSIS
por: Wilding, Hannah, et al.
Publicado: (2023)

SDPS-06 A 4 YEAR-OLD GIRL WITH EMBRYONAL RHABDOMYOSARCOMA IN RETROAURICULAR AND MIDDLE EAR : A RARE CASE REPORT FROM INDONESIA
por: Anugrah, Diko, et al.
Publicado: (2023)

SDPS-05 ASSESSING SURVIVAL OUTCOMES AND COMPLICATION PROFILES FOLLOWING SURGICAL EXCISION OF SKULL BASE CHORDOMA: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

SDPS-18 RHABDOID TUMOR PREDISPOSITION SYNDROME IN TWO INFANT SIBLINGS WITH ATYPICAL TERATOID RHABDOID TUMORS DUE TO A GERMLINE SMARCB1 MUTATION
por: Quintero, Ana, et al.
Publicado: (2023)

SDPS-01 DEVELOPMENT OF A WEB-BASED CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERMSURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

SDPS-29 SERUM-DERIVED CD47 AS A MARKER OF TUMOR BURDENAND OUTCOME IN GBM PATIENTS – CORRELATIVE ANALYSISOF TUMOR LOCATION, RADIATION THERAPY VOLUMES,AND SURVIVAL
por: Jagasia, Sarisha, et al.
Publicado: (2023)

SDPS-09 MIXED RESPONSE OF BRAIN METASTASES TREATED WITH OSIMERTINIB PREDICTS INFERIOR SURVIVAL OUTCOMES: AN ARTIFICIAL INTELLIGENCE-BASED LESION-LEVEL ASSESSMENT FOR CRANIAL CONTROL OF EGFRMUTANT NONSMALL CELL LUNG CANCER
por: Lu, Shao-Lun, et al.
Publicado: (2023)

SYST-13 AAV VECTOR ENCODING FC MODIFIED HER2 ANTIBODIES REDUCES TUMOR BURDEN WITH MINIMIZED PERIPHERAL EXPOSURE IN MODELS OF BREAST CANCER BRAIN METASTASIS
por: Laks, Dan, et al.
Publicado: (2023)

LMAP-15 INTRACRANIAL RADIOTHERAPY WITH TUCATINIB FOR BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER: A SINGLE-INSTITUTION SERIES
por: Khatri, Vaseem, et al.
Publicado: (2023)

TIPS-10 FEASIBILITY OF A MULTI-MODALITY CENTRAL NERVOUS SYSTEM SCREENING EVALUATION IN HER2+ BREASTCANCER PATIENTS
por: Malani, Rachna, et al.
Publicado: (2023)

The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients
por: Memon, A A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_o8hh7r99ud9sr042l0gjkncqfq